AbCellera Biologics Inc. (ABCL) Cash Flow Statement
AbCellera Biologics Inc. (ABCL) generated -$94.9M of operating cash flow over the twelve months to 2026-06-30, spent $24.7M on capital expenditure and had free cash flow of -$119.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABCLAbCellera Biologics Inc.Follow ABCL — free
—
Price chart with a free account
- Market cap
- 3.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.24 | 0.28 | -0.04 | -0.11 | -0.13 | -0.09 | |
| Capital expenditure | 0.06 | 0.07 | 0.08 | 0.08 | 0.04 | -0.02 | |
| Free cash flow | 0.19 | 0.21 | -0.12 | -0.19 | -0.17 | -0.12 | |
| Stock-based compensation | 0.03 | 0.05 | 0.06 | 0.07 | 0.06 | — |
USD billions · SEC XBRL
AbCellera Biologics Inc. — questions
- What is AbCellera Biologics Inc.'s operating cash flow?
- -$94.9M over the twelve months to 2026-06-30.
- How much does AbCellera Biologics Inc. spend on capital expenditure?
- $24.7M over the twelve months to 2026-06-30.
- What is AbCellera Biologics Inc.'s free cash flow?
- -$119.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from AbCellera Biologics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.